title: Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force Recommendation Statement.
abstract: METHODS
  Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on counseling and interventions to prevent tobacco use and tobacco-related disease in adults, including pregnant women.
  
  
  METHODS
  The USPSTF reviewed the evidence on interventions for tobacco smoking cessation that are relevant to primary care (behavioral interventions, pharmacotherapy, and complementary or alternative therapy) in adults, including pregnant women.
  
  
  METHODS
  This recommendation applies to adults aged 18 years or older, including pregnant women.
  
  
  CONCLUSIONS
  The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration-approved pharmacotherapy for cessation to adults who use tobacco. (A recommendation). The USPSTF recommends that clinicians ask all pregnant women about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant women who use tobacco. (A recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant women. (I statement). The USPSTF concludes that the current evidence is insufficient to recommend electronic nicotine delivery systems for tobacco cessation in adults, including pregnant women. The USPSTF recommends that clinicians direct patients who smoke tobacco to other cessation interventions with established effectiveness and safety (previously stated). (I statement).
authors.forename: Albert L
authors.initials: AL
authors.lastname: Siu
mesh_terms: D000328:Adult; D001521:Behavior Therapy; D035843:Biomedical Research; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use; D017281:Cost of Illness; D003376:Counseling; D066300:Electronic Nicotine Delivery Systems / Q000009:adverse effects; D005260:Female; D006801:Humans; D018722:Nicotinic Agonists / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D018570:Risk Assessment; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D061485:Tobacco Use Cessation Devices / Q000009:adverse effects; D014481:United States; D000068580:Varenicline / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D018722:Nicotinic Agonists; D016642:Bupropion; D000068580:Varenicline